ERBB2 and gastric cancer: The current study reported that combination of HER2 amplification and PD‐L1 expression in Chinese patients with gastric cancer could stratify the total populations into several subgroups with distinctive genomic and immune landscapes, which could be sensitive to different therapeutic regimens, indicating that both HER2 status and PD‐L1 expression level should be considered when making personalized treatment decisions for patients with advanced gastric cancer.